Acurx Pharmaceuticals (NASDAQ:ACXP) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

Acurx Pharmaceuticals Stock Performance

ACXP traded down $0.09 during trading on Thursday, hitting $1.68. The stock had a trading volume of 22,556 shares, compared to its average volume of 89,944. The company has a 50 day moving average price of $1.96 and a 200-day moving average price of $2.14. Acurx Pharmaceuticals has a one year low of $1.52 and a one year high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same quarter in the prior year, the firm earned ($0.24) EPS. Research analysts expect that Acurx Pharmaceuticals will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC grew its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 295,075 shares of the company’s stock after purchasing an additional 16,975 shares during the period. Prospect Financial Services LLC owned about 1.86% of Acurx Pharmaceuticals worth $561,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.